CorVel Corporation (CRVL) is a publicly traded company in the Financial Services — Insurance - Brokers industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
CorVel Corporation delivers comprehensive solutions designed to assist employers, third-party administrators, insurance providers, and government entities in effectively managing healthcare claims. The company focuses on controlling medical expenditures and ensuring high-quality care across various sectors, including workers' compensation, auto liability, and general health.
Is CorVel Corporation stock overvalued or undervalued in 2026?
As of October 2, 2026, CorVel Corporation (CRVL) trades at 33.5× earnings (P/E), against a median of 13.0× across the 393 insurance companies above $2bn in Kaplio's universe. Kaplio's verdict: expensive. At a P/B justified by its ROE del 29,9 % (2.0×) $16 (-79 %); at its peers' median (3.2×) $26 (-66 %).
Kaplio overview: CorVel Corporation
Market cap $4B · 52 weeks $46 – $78 (2 % below the high) · P/E 33.5× · Dividend none · Next earnings November 3, 2026 · Price as of Oct 2 · accounts published Aug 5.
- Valuation: P/B 9.4× (expensive).
- Business: 5-year op. margin 13.0 % (solid).
- Balance sheet: Debt/Equity 0.07 (solid).
- Earnings: Next.
What would it be worth at its usual multiples?
At a P/B justified by its ROE del 29,9 % (2.0×) $16 (-79 %); at its peers' median (3.2×) $26 (-66 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
What matters in insurance: 2 of 5 pass
- Book Value / Share growth −8.4 %, fails.
- P/B (Price / Book) 9.4×, fails.
- Dividend growth streak 0 años, fails.
- Op Margin 5y (Combined Ratio proxy) 13.0 %, passes.
- Debt / Equity 0.07, passes.
Against its peers (reference peers) — CorVel Corporation: P/E 33.5×; P/B 9.4×; ROE 29.9 %; $3.8B. PJT Partners Inc. (P/E 15.4×; P/B 11.8×; ROE 71.2 %; $3.6B), Genworth Financial, Inc. (P/E 17.5×; P/B 0.4×; ROE 2.5 %; $3.5B), Federated Hermes, Inc. (P/E 10.3×; P/B 3.2×; ROE 34.1 %; $4.4B).
Expensive or cheap against its last ten fiscal years?
Precio / valor contable at each close: today 9.4× · median 4.4× · minimum 1.6× · maximum 25.6× · cheap below 2.6× · expensive above 16.9×. It has been cheaper than today 62% of the time over its last ten fiscal years.
Profitability
| Return on Equity | 29.93% |
| Return on Invested Capital | 26.37% |
| Return on Assets | 16.72% |
| Gross Margin | 23.90% |
| Operating Margin | 15.37% |
| Net Margin | 11.72% |
Financial Health
| Debt / Equity | 0.07 |
| Current Ratio | 1.94 |
| Piotroski F-Score | 7 |
| Altman Z-Score | 11.63 |
Price Performance
| 1 month | +11.39% |
| 3 months | +20.63% |
| Year-to-date | +12.31% |
| 1 year | +1.86% |
| 3 years | +12.53% |
| 5 years | +28.10% |
Related companies: AGO · ATH · CNO · FG · FHI · GBDC · GNW
Explore sector: Financial Services · Insurance - Brokers
More sections of CRVL: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks